Nicotinic Receptor Agonists for Treating Diseases of Cognitive Dysfunction

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• Diseases Involving Cognitive Dysfunction That Are Prospective Targets for Nicotinic Receptor Agonists
  • Alzheimer' s Disease
  • Mild Cognitive Impairment
  • Age-Associated Memory Impairment
  • Schizophrenia
  • Attention-Defi cit/Hyperactivity Disorder
  • Parkinson' s Disease
• Biology of Nicotinic Receptors
  • Functional Studies of Nicotinic Receptors That Are Targets in Improvement of Cognition
  • Functional Studies of nAChRs Containing the β4 Subunit Using a Subtype-Specific Drug
  • Functional Studies of nAChRs Containing the β2 Subunit Using Genetic Manipulation
  • A Study of the Role of the α7 nAChR in Attention
  • Other Studies of the Potential Role of α7 Receptors in Schizophrenia and Alzheimer' s Disease
• Subtype-Specifi c nAChR Agonists in Clinical Development for Cognitive Disorders
  • Targacept/AstraZeneca' s TC-1734/AZD-3480
  • CoMentis' s GTS-21
  • Memory Pharmaceuticals/Roche' s MEM-3454
  • EnVivo Pharmaceuticals' α7 Agonist Program
  • NeuroSearch/Abbott' s Nicotinic Receptor Agonist Program
• Outlook

Tables:

• 1. Prevalence in the Major Markets of Diseases Involving Cognitive Dysfunction That Are Targets for Nicotinic Acetylcholine Receptor Agonists, 2006
• 2. Properties of Neural Nicotinic Receptor Subtypes That Are Targets in Cognition
• 3. Select Subtype-Specific Nicotinic Receptor Agonists in Development for Cognitive Disorders

Figures:

• 1. Cognition and Memory
• 2. Dopamine Pathways